An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippage

• Published in: Frontiers in immunology Vol. 14; p. 1171083
• Main Authors: Pakola, Santeri, Quixabeira, Dafne C A, Kudling, Tatiana V, Clubb, James H A, Grönberg-Vähä-Koskela, Susanna, Basnet, Saru, Jirovec, Elise, Arias, Victor, Haybout, Lyna, Heiniö, Camilla, Santos, Joao M, Cervera-Carrascon, Victor, Havunen, Riikka, Anttila, Marjukka, Hemminki, Akseli
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 05.07.2023
• Subjects: Adenoviridae; Adenoviridae Infections; adenovirus; Animals; Carcinoma, Pancreatic Ductal - drug therapy; Carcinoma, Pancreatic Ductal - therapy; Cell Line, Tumor; chemotherapy; Cytokines - therapeutic use; Fibroblasts - pathology; Gemcitabine; Immunology; immunotherapy; interleukin 2; Interleukin-2 - genetics; Interleukin-2 - pharmacology; Interleukin-2 - therapeutic use; Lymphocytes - pathology; Mice; oncolytic virus; Pancreatic Neoplasms; Tumor Microenvironment; interleukin 2; chemotherapy; oncolytic virus; adenovirus; immunotherapy
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2023.1171083

Pancreatic ductal adenocarcinoma (PDAC) is a highly treatment-resistant cancer. Currently, the only curative treatment for PDAC is surgery, but most patients are diagnosed with metastatic disease and thus outside the scope of surgery. The majority of metastatic patients receive chemotherapy, but responses are limited. New therapeutics are thus urgently needed for PDAC. One major limitation in treating PDAC has been the highly immunosuppressive tumor microenvironment (TME) which inhibits anti-cancer immune responses. We have constructed an oncolytic adenovirus coding for a variant the interleukin 2 molecule, Ad5/3-E2F-d24-vIL2 (also known as TILT-452, and "vIL-2 virus"), with preferential binding to IL-2 receptors on the surface of effector lymphocytes over T regulatory cells (T regs). In the present study this virus was evaluated in combination with nab-paclitaxel and gemcitabine chemotherapy in Panc02 mouse model. Ad5/3-E2F-d24-vIL2 showed marked PDAC cell killing , alongside induction of mitotic slippage and immunogenic cell death in PDAC cell lines, when combined with chemotherapy. Increased survival was seen with 80% of animals surviving long term, when compared to chemotherapy alone. Moreover, combination therapy mediated enhanced tumor growth control, without observable toxicities in internal organs or external features. Survival and tumor control benefits were associated with activation of tumor infiltrating immune cells, downregulation of inhibitory signals, change in fibroblast populations in the tumors and changes in intratumoral cytokines, with increased chemokine amounts (CCL2, CCL3, CCL4) and anti-tumor cytokines (IFN-γ and TNFα). Furthermore, vIL-2 virus in combination with chemotherapy efficiently induced tumor protection upon rechallenge, that was extended to a previously non-encountered cancer cell line. In conclusion, Ad5/3-E2F-d24-vIL2 is a promising immunotherapy candidate when combined with nab-paclitaxel and gemcitabine.